CHM-029 for Leukemia

This trial tests CHM-029, a new oral medicine, to determine its safety and effectiveness for people with acute myeloid leukemia (AML) that has returned or is unresponsive to treatment. Researchers aim to find the right dose, identify potential side effects, and understand how the body processes the drug. Participants will contribute by taking the medicine and attending regular clinic visits for health checks. The trial seeks adults with AML who have tried standard treatments and possess specific genetic markers, such as the NPM1 mutation. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial information does not specify if you need to stop taking your current medications. However, if you are using hydroxyurea to manage your white blood cell count, you may need to continue it to meet the trial's eligibility criteria.

In a previous study, researchers examined the safety of CHM-029 in 34 patients with acute myeloid leukemia (AML). They found that 24% of patients experienced serious side effects. The most common were anemia (a low red blood cell count) and neutropenia (a low white blood cell count), each affecting 9% of patients.

Another study showed that CHM-029 generally has a tolerable safety profile, meaning most side effects can be managed by adjusting the dose. While some patients may experience side effects, they are often manageable.

Unlike the standard leukemia treatments, which often include chemotherapy and targeted therapies like tyrosine kinase inhibitors, CHM-029 offers a fresh approach. Researchers are excited because CHM-029 is orally administered, which might make it easier for patients to take compared to intravenous options. Moreover, CHM-029 is undergoing dose escalation to find the optimal balance between effectiveness and tolerability, potentially providing a more personalized treatment plan. This new approach could lead to better outcomes and fewer side effects for patients with leukemia.

Research has shown that CHM-029 is a promising treatment for acute myeloid leukemia (AML). This drug targets resistant mutations, which are changes in cancer cells that make treatment more challenging. Studies have demonstrated that CHM-029 performs well in early tests on cells or animals. In this trial, participants will receive CHM-029 in different treatment arms: one involving dose escalation and another involving a backfill at a dose level already evaluated. Menin inhibitors, a group of drugs that includes CHM-029, have shown response rates of 45% to 65% in patients with difficult-to-treat AML. These early results suggest that CHM-029 could be effective against some of the toughest cases of AML.⁶⁷⁸⁹¹⁰